Quick Search 
Drugs of Today
Register or sign in

  
 
  
Drugs Today 2006, 42(12): 791
ISSN 1699-3993
e-ISSN 1699-4019
Copyright 2006 Clarivate
CCC: 1699-3993
DOI: 10.1358/dot.2006.42.12.1025703
 
 
Interleukin-2 for the treatment of human immunodeficiency virus infection
Temesgen, Z.
 
 
Notwithstanding the significant impact of highly active antiretroviral therapy (HAART) on human immunodeficiency virus (HIV)-associated morbidity and mortality, HAART-induced immune restitution is not complete. The potential utility of interleukin (IL)-2 to augment immune function has been extensively evaluated. Intravenous or subcutaneous IL-2 has been conclusively shown to induce significant increases in CD4 cell counts in HIV-infected patients, in particular when given concomitantly with HAART. Large randomized clinical trials are underway to investigate whether these CD4 cell increments will result in tangible clinical benefits.


Full Text: HTMLPDF 
 
  



© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences